Opus Genetics (IRD) Price & Analysis

Compare

1,179 Followers

IRD Stock Chart & Stats

$2.00

$0.08(5.63%)

At close: Jan 08 4:00 PM EST

$2.00

$0.08(5.63%)

Day’s Range― - ―

52-Week Range$0.65 - $2.16

Previous CloseN/A

Volume154.21K

Average Volume (3M)431.43K

Market Cap

$121.61M

Enterprise Value$28.28M

Total Cash (Recent Filing)$32.43M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Nov 18, 2025

EPS Estimate

-0.13

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.12

Shares Outstanding59,908,054

10 Day Avg. Volume559,975

30 Day Avg. Volume431,433

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)4.73

Price to Sales (P/S)2.89

P/FCF Ratio-1.24

Enterprise Value/Market Cap0.23

Enterprise Value/Revenue1.83

Enterprise Value/Gross Profit2.26

Enterprise Value/Ebitda-0.48

Forecast

1Y Price Target

$7.75

Price Target Upside287.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Efficacy And Clinical SuccessThe lead candidate demonstrated consistent efficacy across multiple measures in patients with severe visual impairment, showing improvement in visual acuity and sensitivity.

Market OpportunityOpus Genetics has an AAV gene therapy portfolio targeting an estimated market opportunity of over $10 billion in inherited retinal diseases.

Regulatory ApprovalsThe ophthalmic solution developed in collaboration with a partner has already received FDA approval and reported positive Phase 3 data for additional indications.

Bears Say

Opus Genetics News

Opus Genetics announces $23M registered direct offering

The financing, which included new and existing institutional investors, was led by Perceptive Advisors and Balyasny Asset Management,...

3d ago

IRD

Opus Genetics announces completion of Type B RMAT meeting with FDA

Opus Genetics (IRD) announced completion of a Type B Regenerative Medicine Advanced Therapy meeting with the U.S. Food...

3d ago

IRD

Opus Genetics announces work featured on Good Morning America

Opus Genetics (IRD) announced that its work was featured on Good Morning America in honor of World Blindness...

6d ago

IRD

Wedbush starts Opus with Outperform on gene therapy potential

As previously reported, Wedbush analyst Yun Zhong initiated coverage of Opus Genetics (IRD) with an Outperform rating and...

10d ago

IRD

Opus Genetics initiated with an Outperform at Wedbush

Wedbush initiated coverage of Opus Genetics (IRD) with an Outperform rating and $8 price target Published first on...

11d ago

IRD

Opus Genetics initiated with a Buy at Chardan

Chardan initiated coverage of Opus Genetics (IRD) with a Buy rating and $9 price target The firm cites...

24d ago

IRD

Opus Genetics Announces $23M Direct Offering

Opus Genetics ( ($IRD) ) has issued an announcement. On November 5, 2025, Opus Genetics, Inc. entered into...

2d ago

IRD

Positive Outlook for Opus Genetics: Regulatory Support and Financial Stability Justify Buy Rating

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Opus Genetics. The associated price target remains...

2d ago

IRD

Opus Genetics Announces $23 Million Direct Offering

Opus Genetics ( ($IRD) ) just unveiled an announcement. On November 6, 2025, Opus Genetics announced a $23...

3d ago

IRD

Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know

Opus Genetics, Inc. (($IRD)) announced an update on their ongoing clinical study. Opus Genetics, Inc. is conducting a...

12d ago

IRD

Opus Genetics Advances Genetic Therapy for Rare Eye Conditions

Opus Genetics, Inc. (($IRD)) announced an update on their ongoing clinical study. Opus Genetics, Inc. is conducting a...

12d ago

IRD

Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update

Opus Genetics, Inc. (($IRD)) announced an update on their ongoing clinical study. Opus Genetics, Inc. is conducting a...

12d ago

IRD

Opus Genetics: Promising Gene Therapy Developments and Strategic Advancements Drive Buy Rating

JonesTrading analyst Debanjana Chatterjee maintained a Buy rating on Opus Genetics today and set a price target of...

13d ago

IRD

Opus Genetics’ Promising Prospects: Buy Rating Reinforced by OPGx-LCA5 Efficacy and Strategic Advancements

Analyst Debanjana Chatterjee of JonesTrading reiterated a Buy rating on Opus Genetics, retaining the price target of $6.00....

1M ago

IRD

IRD FAQ

What was Opus Genetics’s price range in the past 12 months?

Opus Genetics lowest stock price was $0.65 and its highest was $2.16 in the past 12 months.

What is Opus Genetics’s market cap?

Opus Genetics’s market cap is $121.61M.

When is Opus Genetics’s upcoming earnings report date?

Opus Genetics’s upcoming earnings report date is Nov 18, 2025 which is in 9 days.

How were Opus Genetics’s earnings last quarter?

Opus Genetics released its earnings results on Aug 13, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.085.

Is Opus Genetics overvalued?

According to Wall Street analysts Opus Genetics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Opus Genetics pay dividends?

Opus Genetics does not currently pay dividends.

What is Opus Genetics’s EPS estimate?

Opus Genetics’s EPS estimate is -0.13.

How many shares outstanding does Opus Genetics have?

Opus Genetics has 59,908,054 shares outstanding.

What happened to Opus Genetics’s price movement after its last earnings report?

Opus Genetics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went up 7.273%.

Which hedge fund is a major shareholder of Opus Genetics?

Currently, no hedge funds are holding shares in IRD

Opus Genetics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-200.57%

Trailing 12-Months

Asset Growth

-13.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Opus Genetics

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Opus Genetics (IRD) Earnings & Revenues

Historic Earnings Reports

IRD Stock 12 Month Forecast

Average Price Target

$7.75

▲(287.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.3,2.815384615384615,3.3307692307692305,3.8461538461538463,4.361538461538462,4.876923076923077,5.392307692307693,5.907692307692308,6.423076923076923,6.938461538461539,7.453846153846154,7.969230769230769,8.484615384615385,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.3,2.719230769230769,3.1384615384615384,3.5576923076923075,3.976923076923077,4.396153846153846,4.815384615384615,5.234615384615385,5.653846153846153,6.073076923076923,6.492307692307692,6.911538461538462,7.3307692307692305,{"y":7.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.3,2.5846153846153843,2.869230769230769,3.1538461538461537,3.4384615384615382,3.7230769230769227,4.007692307692308,4.292307692307692,4.576923076923077,4.861538461538461,5.146153846153846,5.430769230769231,5.715384615384615,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.24,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >